Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.
Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.
复制标题
DOI：
10.1089/vim.2022.0104
复制
发表时间：
2023-01
期刊：
影响因子：
2.2
通讯作者：
Vanlandingham, Dana L.
中科院分区：
文献类型：
--
作者：
Ayers, Victoria B.;Huang, Yan-Jang S.;Dunlop, James I.;Kohl, Alain;Brennan, Benjamin;Higgs, Stephen;Vanlandingham, Dana L.
裂谷热病毒(RVFV)是一种新出现的虫媒病毒，对反刍动物和人类都有影响。RVFV在非洲和阿拉伯半岛造成严重和反复的暴发，并有出现在新地点的重大风险。虽然流行地区使用的RVFV兽用疫苗种类繁多，但目前还没有人类使用的许可疫苗；因此，有必要开发和评估新的疫苗。在此，我们报告了一种RVFV减毒活疫苗候选疫苗，该候选疫苗基于先前描述的有条件许可的MP12疫苗的基因组重组。目前有两种常用的RVFV减毒活疫苗策略，一种是用野生型RVFV毒株进行连续传代，以筛选减毒突变株，如Smithburn、Clone 13和MP12疫苗株。第二种策略利用反向遗传学通过在病毒基因组中引入缺失或插入来减弱RVFV毒株。本报告中描述的新型候选疫苗包含一个两个片段的基因组，其中缺少中等病毒片段(M)和两个毒力基因(非结构小基因和非结构中基因)。该候选疫苗名为r2SegMP12，用于在杂交CD-1小鼠中产生RVFV中和抗体。将r2SegMP12候选疫苗诱导的免疫应答与rMP12亲本株疫苗诱导的免疫应答直接进行比较。我们的研究表明，r2SegMP12候选疫苗在105个空斑形成单位的单次免疫比相同滴度的rMP12疫苗在不需要增强剂的情况下产生更高的中和抗体应答。
Rift Valley fever virus (RVFV) is an emerging arbovirus that affects both ruminants and humans. RVFV causes severe and recurrent outbreaks in Africa and the Arabian Peninsula with a significant risk for emergence into new locations. Although there are a variety of RVFV veterinary vaccines for use in endemic areas, there is currently no licensed vaccine for human use; therefore, there is a need to develop and assess new vaccines. Herein, we report a live-attenuated recombinant vaccine candidate for RVFV, based on the previously described genomic reconfiguration of the conditionally licensed MP12 vaccine. There are two general strategies used to develop live-attenuated RVFV vaccines, one being serial passage of wild-type RVFV strains to select attenuated mutants such as Smithburn, Clone 13, and MP12 vaccine strains. The second strategy has utilized reverse genetics to attenuate RVFV strains by introducing deletions or insertions within the viral genome. The novel candidate vaccine characterized in this report contains a two-segmented genome that lacks the medium viral segment (M) and two virulence genes (nonstructural small and nonstructural medium). The vaccine candidate, named r2segMP12, was evaluated for the production of neutralizing antibodies to RVFV in outbred CD-1 mice. The immune response induced by the r2segMP12 vaccine candidate was directly compared to the immune response induced by the rMP12 parental strain vaccine. Our study demonstrated that a single immunization with the r2segMP12 vaccine candidate at 105 plaque-forming units elicited a higher neutralizing antibody response than the rMP12 vaccine at the same vaccination titer without the need for a booster.
登录
查看更多内容
影响因子：
3.2
作者：
Ayers VB;Huang YS;Lyons AC;Park SL;Higgs S;Dunlop JI;Kohl A;Alto BW;Unlu I;Blitvich BJ;Vanlandingham DL
通讯作者：
Vanlandingham DL
影响因子：
4.8
作者：
Kamal SA
通讯作者：
Kamal SA
DOI：
10.3390/v3050493
发表时间：
2011-05
期刊：
Viruses
影响因子：
--
作者：
Ikegami T;Makino S
通讯作者：
Makino S
影响因子：
5.5
作者：
Julander, Justin G.;Trent, Dennis W.;Monath, Thomas P.
通讯作者：
Monath, Thomas P.
影响因子：
1.7
作者：
Abdo-Salem, Shaif;Waret-Szkuta, Agnes;Chevalier, Veronique
通讯作者：
Chevalier, Veronique